We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$71.7M
AUM Growth
+$18M
Cap. Flow
+$11.5M
Cap. Flow %
16.1%
Top 10 Hldgs %
66.95%
Holding
32
New
12
Increased
6
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$3.63M
2
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$3.11M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$2.7M
4
INGN icon
Inogen
INGN
+$2.24M
5
PTCT icon
PTC Therapeutics
PTCT
+$1.64M

Top Sells

Rank Stock Value
1
IPXL
Impax Laboratories, Inc.
IPXL
+$2.2M
2
DVA icon
DaVita
DVA
+$1.25M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$1.16M
4
EW icon
Edwards Lifesciences
EW
+$956K
5
INCY icon
Incyte
INCY
+$943K

Sector Composition

Rank Sector Weight
1 Healthcare 90.17%
2 Industrials 6.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
26
Regenxbio
RGNX
$691M
$239K 0.33%
+12,398
New +$239K
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
$204K 0.28%
3,200
-12,632
-80% -$768K
DVA icon
28
DaVita
DVA
$11.4B
– –
-19,451
Closed -$1.25M
EW icon
29
Edwards Lifesciences
EW
$51.7B
– –
-30,600
Closed -$956K
NTRA icon
30
Natera
NTRA
$45.3B
– –
-59,300
Closed -$694K
PRGO icon
31
Perrigo
PRGO
$1.78B
– –
-10,339
Closed -$861K
IPXL
32
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-166,099
Closed -$2.2M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Asymmetry Capital Management held 32 positions worth $71.7M, up 33% from $53.8M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Asymmetry Capital Management deployed $11.5M of net new capital in Q1 2017, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was GSK: 71,612 shares worth $3.77M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $1.16M trimmed.

  • Asymmetry Capital Management's largest Q1 2017 buy was GSK: 71,612 shares worth $3.77M.
  • Asymmetry Capital Management added most to Synergy Pharmaceuticals, Inc Common Stock in Q1 2017, an estimated $3.11M increase.
  • Asymmetry Capital Management's biggest Q1 2017 reduction was Jazz Pharmaceuticals, cutting an estimated $1.16M.
  • Asymmetry Capital Management fully exited Impax Laboratories, Inc. in Q1 2017, selling an estimated $2.2M.
  • Asymmetry Capital Management's ten largest holdings make up 67% of its $71.7M portfolio in Q1 2017.
  • Asymmetry Capital Management opened 12 new positions and closed 5 in Q1 2017.
  • Asymmetry Capital Management's portfolio value rose 33% quarter-over-quarter to $71.7M.

Based on Asymmetry Capital Management's 13F filing for Q1 2017, filed 12 May 2017.